Bavarian Nordic Dirección

Dirección controles de criterios 4/4

Bavarian Nordic's CEO is Paul Chaplin, appointed in Jun 2014, has a tenure of 9.92 years. total yearly compensation is DKK23.43M, comprised of 30.7% salary and 69.3% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $1.99M. The average tenure of the management team and the board of directors is 4.2 years and 3.3 years respectively.

Información clave

Paul Chaplin

Chief Executive Officer (CEO)

kr.23.4m

Compensación total

Porcentaje del salario del CEO	30.7%
Permanencia del CEO	9.9yrs
Participación del CEO	0.1%
Permanencia media de la dirección	4.2yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul Chaplin en comparación con los beneficios de Bavarian Nordic?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	kr.984m
Dec 31 2023	kr.23m	kr.7m	kr.1b
Sep 30 2023	n/a	n/a	kr.723m
Jun 30 2023	n/a	n/a	kr.1b
Mar 31 2023	n/a	n/a	kr.301m
Dec 31 2022	kr.22m	kr.6m	-kr.347m
Sep 30 2022	n/a	n/a	-kr.599m
Jun 30 2022	n/a	n/a	-kr.693m
Mar 31 2022	n/a	n/a	-kr.606m
Dec 31 2021	kr.18m	kr.6m	-kr.465m
Sep 30 2021	n/a	n/a	-kr.737m
Jun 30 2021	n/a	n/a	-kr.629m
Mar 31 2021	n/a	n/a	-kr.368m
Dec 31 2020	kr.14m	kr.5m	kr.278m
Sep 30 2020	n/a	n/a	kr.606m
Jun 30 2020	n/a	n/a	kr.481m
Mar 31 2020	n/a	n/a	kr.267m
Dec 31 2019	kr.12m	kr.5m	-kr.347m
Sep 30 2019	n/a	n/a	-kr.402m
Jun 30 2019	n/a	n/a	-kr.271m
Mar 31 2019	n/a	n/a	-kr.279m
Dec 31 2018	kr.12m	kr.6m	-kr.362m
Sep 30 2018	n/a	n/a	-kr.445m
Jun 30 2018	n/a	n/a	-kr.151m
Mar 31 2018	n/a	n/a	kr.5m
Dec 31 2017	kr.13m	kr.5m	kr.181m

Compensación vs. Mercado: La compensación total de Paul($USD3.37M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD5.61M).

Compensación vs. Ingresos: La compensación de Paul ha sido consistente con los resultados de la empresa en el último año.

CEO

Paul Chaplin (56 yo)

9.9yrs

Permanencia

kr.23,428,000

Compensación

Dr. Paul John Chaplin, M.Sc., Ph D., has been the Chief Executive Officer and President at Bavarian Nordic A/S since May 28, 2014. Dr. Chaplin served as an Executive Vice President of Bavarian Nordic A/S f...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Chaplin	CEO & President	9.9yrs	kr.23.43m	0.11% DKK 2.0m
Henrik Juuel	CFO & Executive VP	5.5yrs	kr.12.23m	sin datos
Russell Thirsk	Executive VP & COO	2.1yrs	sin datos	sin datos
Rolf Sørensen	Vice President of Investor Relations & Communications	no data	sin datos	sin datos
Anu Kerns	Executive VP and Chief People & Sustainability Officer	3.5yrs	sin datos	sin datos
Jean-Christophe May	Executive VP & Chief Commercial Officer	4.3yrs	sin datos	sin datos
Laurence De Moerlooze	Executive VP & Chief Medical Officer	4.1yrs	sin datos	sin datos

4.2yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BVNK.F se considera experimentado (4.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Kürstein-Jensen	Independent Director	12.1yrs	kr.740.00k	0.026% DKK 483.6k
Anders Pedersen	Deputy Chairman	14.1yrs	kr.1.13m	0.024% DKK 446.1k
Franciscus A. G. Verwiel	Independent Director	8.1yrs	kr.830.00k	0.0055% DKK 101.4k
Anne Eberhard	Independent Director	5.1yrs	kr.860.00k	0.0035% DKK 63.8k
Luc Debruyne	Independent Chairman	1.2yrs	kr.1.43m	sin datos
Heidi Hunter	Independent Director	1.3yrs	kr.635.00k	sin datos
Linette Munksgaard Andersen	Employee-Elected Member of the Board	3.3yrs	kr.475.00k	0.00070% DKK 12.8k
Thomas Alex Bennekov	Employee-Elected Member of the Board	3.3yrs	kr.475.00k	0.0024% DKK 43.8k
Anja Gjol	Employee-Elected Member of the Board	3.3yrs	kr.475.00k	0.00070% DKK 12.8k
Karen Merete Jensen	Employee-Elected Member of the Board	3.3yrs	kr.475.00k	0.00088% DKK 16.1k
Johan Hoof	Independent Director	1.3yrs	kr.575.00k	sin datos
Montse Picart	Director	less than a year	sin datos	sin datos

3.3yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de BVNK.F se considera experimentada (3.3 años de antigüedad promedio).

Bavarian Nordic Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S Announces Appointment of Anu Helena Kerns as Executive Vice President, People and Organization, Effective from November 2020

Recent updates

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2021

Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

Bavarian Nordic A/S Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine

Bavarian Nordic A/S Maintains Earnings Guidance for the Full Year 2021

Bavarian Nordic A/S has completed a Follow-on Equity Offering in the amount of DKK 1.14845 billion.

Bavarian Nordic A/S Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial

Bavarian Nordic to Supply Smallpox Vaccines to Three European Countries

Bavarian Nordic A/S Announces Top-line Results from Phase 2 Clinical Trial of BN-Brachyury in Chordoma

Bavarian Nordic A/S Secures Second Part of Smallpox Vaccine Order from the U.S. Government

Health Canada Extends Approval of IMVAMUNE to Immunization Against Monkeypox and Orthopox Viruses

Bavarian Nordic A/S to Report Q2, 2021 Results on Aug 25, 2021

Bavarian Nordic A/S Announces Appointment of Anu Helena Kerns as Executive Vice President, People and Organization, Effective from November 2020

Bavarian Nordic A/S to Report Fiscal Year 2020 Results on Mar 12, 2021

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad